Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Abstract Small cell lung cancer (SCLC) comprises about 15% of all cases of lung cancer. In recent years, owing to a change in the epidemiology of smoking habits, the incidence of the tumor has decreased; however, it remains a significant challenge to global health. While the tumor has a favorable in...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Adis, Springer Healthcare
2018-09-01
|
| coleção: | Drugs in R&D |
| Acesso em linha: | http://link.springer.com/article/10.1007/s40268-018-0247-7 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|